



The 15th International Congress of the
Society for Melanoma Research
 October 24 - 27, 2018



*Manchester
 England*

SMR Congress Agenda 2018

Wednesday 24th October

Time	Function	Presenters	Location
12:00pm-6:00pm	Registration Open		Charter Foyer
5:30pm - 7:30pm	Opening Session		Exchange Hall
5:30pm - 6:20pm	Opening	Keith Flaherty & Richard Marais	
6:20pm - 7:30pm	Keynote Presentation - Advancing melanoma therapy through team science	Jennifer Wargo	
7:30pm - 9:30pm	Welcome Reception (with Exhibitors and Posters)		Gallery & Charter 1-3

Thursday 25th October

Time	Function	Presenters	Location
7:00am-6:00pm	Registration Open		Charter Foyer
8:00am - 9:45am	Plenary Session 1 - Immunotherapy		Exchange Hall
8:00am - 8:30am	Redirecting bifurcate TNF signaling by TRAF2/cIAP complex inhibition sensitizes to immunotherapy	David Vredevogd	
8:30am - 9:00am	UVB-induced tumor heterogeneity directs immune response in melanoma	Yardena Samuels	
9:00am - 9:15am	Role of melanoma MHC fucosylation in CD4+ T cell-mediated tumor suppression	Daniel Lester	
9:15am - 9:45am	Overcoming resistance to PD-1 blockade therapy	Antoni Ribas	
9:45am - 10:15am	Morning Break		Gallery & Charter 1-3
10:15am - 12:00pm	Plenary Session 2 - Late Breaking Clinical Updates		Exchange Hall
10:15am - 10:45am	Featured Presentation from the 2018 Estella Medrano Award Recipient- Melanoma treatment and Protein Translational Control	Caroline Robert	

10:45am - 11:00am	EOMES+CD45RO+ effector memory T-cells determine response to combined anti-PD-1/anti-CTLA-4 immunotherapy but not to anti-PD-1 monotherapy	Tuba Gide	
11:00am - 11:15am	Sexual dimorphism in response to BRAFmut melanoma targeted therapy	Miles Andrews	
11:15am - 11:30am	Prognostic and predictive value of AJCC-8 staging in the phase 3 EORTC 1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma	Caroline Robert	
11:30am - 11:45am	5-year outcomes in patients (pts) with ipilimumab (ipi)-refractory melanoma treated with pembrolizumab (pembro) in KEYNOTE-002	Antoni Ribas	
11:45am - 12:00pm	Long-term follow-up of standard-dose pembrolizumab (pembro) plus reduced-dose ipilimumab (ipi) in 153 patients (pts) with advanced melanoma (MEL): KEYNOTE-029 1B	Georgina Long	
12:00pm - 1:30pm	Lunch, Poster and Exhibitor Viewing		Gallery & Charter 1-3
12:15pm - 1:15pm	The Pursuit of Survival in Advanced Melanoma A lunchtime symposium organized and funded by MSD		Exchange Hall
12:15pm - 12:25pm	Welcome and Introduction	Paul Lorigan	
12:25pm - 12:40pm	Translating Endpoints Into Clinical Practice: What Have We Learned?	Marianne Nicolson	
12:40pm - 12:55pm	Further Optimising the Treatment Pathway for Patients With Advanced Melanoma	Caroline Robert	
12:55pm - 1:15pm	Q&A and Panel Discussion	Moderated by Paul Lorigan	
12:15pm - 1:15pm	Navigating the Evolving Melanoma Treatment Landscape: A Case-based Discussion A lunchtime symposium organized and funded by Novartis		Exchange Auditorium
12:15pm - 12:20pm	Welcome: Decision Points in the Treatment of Melanoma	Paul Nathan	
12:20pm - 1:05pm	Case-Based Panel Discussion <ul style="list-style-type: none"> • New Choices: Focus on Adjuvant • More Choices: Implications for Metastatic Melanoma • Optimising Choices: Management of Adverse Events 	Keith Flaherty Paul Nathan Elisabetta Pennacchioli	
1:05pm - 1:15pm	Q&A and Closing Remarks	Paul Nathan	
1:30pm - 3:15pm	Concurrent Session 1A - Melanoma Epigenetics		Exchange Hall
1:30pm - 2:00pm	<i>Are mutations enough for UV-induced melanomagenesis?</i>	Raza Zaidi	
2:00pm - 2:15pm	RNA binding kinase UHMK1 regulates therapy induced metabolic adaptation in BRAFV600 melanoma	Lorey Smith	

2:15pm - 2:30pm	Bi-allelic loss of CDKN2A initiates melanoma invasion via BRN2 activation	Hanlin Zeng	
2:30pm - 2:45pm	The RNA helicase DDX3X dictates translation re-programming and drives therapy resistance in melanoma	Bengt Phung	
2:45pm - 3:15pm	<i>Targeting ligand-activated BMP signaling in melanoma</i>	Craig Ceol	
1:30pm - 3:15pm	Concurrent Session 1B - Rare Melanoma Subtypes		Exchange Auditorium
1:30pm - 2:00pm	<i>An update on ocular (uveal and conjunctival) melanomas</i>	Sarah Coupland	
2:00pm - 2:15pm	Clinical application of circulating tumour cells and circulating tumour DNA in uveal melanoma	Elin Gray	
2:15pm - 2:30pm	Comprehensive genomic profiling of acral and mucosal melanomas identifies potential therapeutic strategies	Kasey Coutts	
2:30pm - 2:45pm	Outcomes for patients with metastatic uveal melanoma (MUM) treated with ipilimumab and nivolumab (cIN): a multi-center, retrospective study	Yana Najjar	
2:45pm - 3:15pm	<i>Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets</i>	Nick Hayward	
3:15pm - 3:45pm	Afternoon Break		Gallery & Charter 1-3
3:45pm - 5:45pm	Plenary Session 3 - Melanoma Biology		Exchange Auditorium
3:45pm - 4:15pm	<i>Clues from melanoma pathogenesis to enhancing preventative and therapeutic strategies</i>	David Fisher	
4:15pm - 4:45pm	<i>Brn2 controls melanomagenesis initiation and progression through PI3K signaling in vivo</i>	Lionel Larue	
4:45pm - 5:15pm	<i>Pivotal role of metabolism in the switch of melanoma cells towards an invasive and drug-resistant phenotype</i>	Corine Bertoloto	
5:15pm - 5:45pm	<i>Epigenetic control of melanoma initiation, progression, and therapy response</i>	Lukas Sommer	
5:45pm - 7:00pm	Poster Reception		Charter 1-3
Friday 26th October			
Time	Function	Presenters	Location
7:00am-5:00pm	Registration Open		Charter Foyer
8:00am - 9:45am	Plenary Session 4 - Tumor Microenvironment		Exchange Hall
8:00am - 8:30am	<i>Imaging melanoma heterogeneity and therapy failure</i>	Eric Sahai	
8:30am - 9:00am	<i>A wrinkle in TiME: How the aged TME promotes tumor progression</i>	Ashani Weeraratna	
9:00am - 9:30am	<i>The actomyosin cytoskeleton in melanoma: beyond cell migration</i>	Victoria Sanz-Moreno	

9:30am - 9:45am	IFN γ -Activated dermal lymphatic vessels inhibit cytotoxic CD8+ T cells in melanoma	Amanda Lund	
9:45am - 10:15am	Morning Break		Gallery & Charter 1-3
10:15am - 12:00pm	Plenary Session 5 - Metabolic Programing		Exchange Hall
10:15am - 10:45am	<i>Adipocytes, fatty acids and the origins of metabolic traits</i>	Richard White	
10:45am - 11:00am	Age induced metabolic rewiring of fibroblasts and melanoma cells to drive therapy resistance	Gretchen Alicea	
11:00am - 11:15am	Oxidative Phosphorylation (OXPHOS): A feature, driver, and therapeutic target in melanoma brain metastases (MBMs)	Grant Fischer	
11:15am - 11:30am	Metabolic regulator PGC1 α suppresses WNT5A-YAP axis to regulate melanoma metastasis and resistance to BRAFV600E inhibition	Chi Luo	
11:30am - 12:00pm	<i>Rewiring of amino acids metabolism in cancer affects the response to immunotherapy</i>	Ayelet Erez	
12:00pm - 1:30pm	Lunch, Poster and Exhibitor Viewing		Gallery & Charter 1-3
12:15pm - 1:15pm	Adjuvant Nivolumab Therapy: How Do We Integrate it Into the Melanoma Treatment Pathway? <i>A lunchtime symposium organized and funded by Bristol-Myers Squibb</i>		Exchange Hall
12:15pm - 12:20pm	Welcome and Introduction	Paul Lorigan	
12:20pm - 12:35pm	Update from CheckMate 238: A Phase 3 Trial of Adjuvant Nivolumab Therapy After Complete Resection in Patients with Stage III/IV Melanoma	Mark Middleton	
12:35pm - 12:50pm	Proposed New Models of Care for the Delivery of Adjuvant Therapies at Guy's Cancer	Mark Harries	
12:50pm - 1:10pm	The Melanoma Treatment Journey: An Interactive Discussion	Paul Lorigan/All faculty	
1:10pm - 1:15pm	Summary and Close	Paul Lorigan	
1:30pm - 3:15pm	Concurrent Session 2A - Melanoma and UVR Genomics		Exchange Hall
1:30pm - 2:00pm	<i>How ageing affects melanoma</i>	Amaya Viros	
2:00pm - 2:15pm	The landscape of driver mutations in cutaneous melanoma	Ian Watson	
2:15pm - 2:30pm	Whole-exome sequencing of acquired nevi identifies mechanisms for development and maintenance of benign neoplasms	Mitchell Stark	
2:30pm - 2:45pm	Dissecting role of ultraviolet radiation exposure patterns in V600EBRAF driven melanoma	Piyushkumar Mundra	

2:45pm - 3:15pm	<i>Do we understand yet the relationship between sun exposure and melanoma risk?</i>	<i>Julia Newton Bishop</i>	
1:30pm - 3:15pm	Concurrent Session 2B - Signaling		Exchange Auditorium
1:30pm - 2:00pm	<i>Wild-type KRAS as a novel player in melanoma</i>	<i>Anja Bosserhoff</i>	
2:00pm - 2:15pm	MYC and NF-κB signalling play a role in shaping the immune response to melanoma	Joanna Pozniak	
2:15pm - 2:30pm	Myosin II reactivation and cytoskeletal remodelling as a hallmark and a vulnerability in melanoma therapy resistance	Jose Orgaz	
2:30pm - 2:45pm	RAB27A promotes melanoma cell invasion and metastasis via regulation of pro-invasive exosomes	Nikolas Haas	
2:45pm - 3:15pm	<i>Targeting MAPKi resistance in NRAS mutant melanoma</i>	<i>Jessie Villanueva</i>	
3:15pm - 3:45pm	Afternoon Break		Gallery & Charter 1-3
3:45pm - 5:30pm	Concurrent Session 3A - Prevention and Early Detection		Exchange Hall
3:45pm - 4:15pm	<i>Clinical and molecular biomarkers for melanoma survival</i>	<i>Marianne Berwick</i>	
4:15pm - 4:30pm	Molecular profiling of primary cutaneous melanomas reveals pathways predisposing to brain metastases	Roy Rabbie	
4:30pm - 4:45pm	Consensus clustering of early stage melanoma reveals transcriptomic signatures with prognostic value	Rohit Thakur	
4:45pm - 5:00pm	In silico functional analysis of GWAS hits suggests mechanisms of predisposition to melanoma and longer telomere length	Carla Robles-Espinoza	
5:00pm - 5:30pm	<i>Oregon's war on melanomaTM: an early detection project</i>	<i>Sancy Leachman</i>	
3:45pm - 5:30pm	Concurrent Session 3B - Tumor Microbiome		Exchange Auditorium
3:45pm - 4:15pm	<i>Coordinated regulation of gut microbiota and anti-tumor immunity by the UPR controls melanoma growth</i>	<i>Ze'ev Ronai</i>	
4:15pm - 4:30pm	The gut microbiome of melanoma patients is distinct from that of healthy individuals and is impacted by probiotic and antibiotic use	Jennifer McQuade	
4:30pm - 4:45pm	Preliminary results from a microbiome-based phase I clinical trial - fecal microbiota transplantation in metastatic melanoma patients who failed immunotherapy (NCT03353402)	Erez Baruch	
4:45pm - 5:00pm	NK cells in the context of MHC class I downregulation in stage IV melanoma patients treated with anti-PD-1	Hansol Lee	

5:00pm - 5:30pm	<i>High-resolution metagenomic analysis of melanoma patient's microbiota during checkpoint inhibitor immunotherapy</i>	<i>Hilary Browne</i>	
5:30pm - 5:40pm	Break		
5:40pm - 6:40pm	Women in Science		Exchange Hall
7:30pm - 11:30pm	Awards Ceremony (Must purchase tickets to attend)		Imperial War Museum
Saturday 27th October			
Time	Function	Presenters	Location
7:30am - 11:00am	Registration Open		Charter Foyer
8:00am - 9:45am	Plenary Session 6 - Heterogeneity and Evolution		Exchange Hall
8:00am - 8:30am	<i>Immunogenomic heterogeneity in patients treated with immunotherapy</i>	<i>Goran Jonsson</i>	
8:30am - 8:45am	Mitfalow zebrafish melanomas reveal transcriptional signature subdivision and lineage-independent subpopulations in vivo	Jana Travnickova	
8:45am - 9:15am	<i>Toward minimal residual disease-directed therapy in melanoma</i>	<i>Jean Christopher Marine</i>	
9:15am - 9:45am	<i>Evolution of metastatic melanoma</i>	<i>Samra Turajlic</i>	
9:45am - 10:15am	Morning Break		Gallery & Charter 1-3
10:15am - 11:30am	Plenary Session 7 - Therapy Resistance		Exchange Hall
10:15am - 10:45am	<i>Therapy resistance in the clinic and in the Lab</i>	<i>Georgina Long</i>	
10:45am - 11:00am	Comparative screening of skin-derived NCSCs, melanocytes, and melanoma developmental programs reveals LPAR1 in MAPKi resistance	Vito Rebecca	
11:00am - 11:30pm	<i>Targeted therapy: adaptations and arrested developments</i>	<i>Andrew Aplin</i>	
11:30pm - 11:45pm	Closing Remarks		Exchange Hall

*Presenters Listed in Italics Represent Invited Faculty